Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

140.06
+0.87000.63%
Post-market: 141.000.9400+0.67%19:30 EDT
Volume:760.30K
Turnover:106.23M
Market Cap:9.06B
PE:135.98
High:141.71
Open:140.99
Low:138.37
Close:139.19
52wk High:160.81
52wk Low:62.24
Shares:64.71M
Float Shares:63.17M
Volume Ratio:0.97
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-2.0500
ROE:10.98%
ROA:4.55%
PB:10.77
PE(LYR):-68.32

Loading ...

Protagonist Says FDA Approves Takeda’s Mimrylo for Polycythemia Vera Erythrocytosis

Reuters
·
Aug 29

US FDA Approves Takeda, Protagonist's Drug for Rare Blood Cancer

Reuters
·
Aug 29

Protagonist Therapeutics Grants Inducement Equity Awards for 7,175 Shares to New Hires at USD 155.1 Strike Price

Reuters
·
Aug 19

Protagonist Therapeutics is Maintained at Outperform by BMO Capital

Dow Jones
·
Aug 17

Protagonist Therapeutics price target raised to $178 from $112 at BMO Capital

TIPRANKS
·
Aug 17

Protagonist Therapeutics, Inc. : Bmo Raises Target Price to $178 from $112

THOMSON REUTERS
·
Aug 17

Protagonist Therapeutics (PTGX) Is Up 6.3% After Swing To Q2 Profitability And ESOP Usage Shift

Simply Wall St.
·
Aug 17

Protagonist Therapeutics CEO Dinesh V. Patel Disposes of USD 14.89 Million in Common Shares

Reuters
·
Aug 13

Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says

MT Newswires Live
·
Aug 11

Protagonist Therapeutics Price Target Raised to $170.00/Share from $145.00 by Truist Securities

Dow Jones
·
Aug 11

Silence Therapeutics Jumps After Mid-Stage Trial Data for Blood Cancer Drug

Reuters
·
Aug 11

Protagonist Therapeutics price target raised to $170 from $145 at Truist

TIPRANKS
·
Aug 10

Protagonist Therapeutics (PTGX) Receives a Buy from Wedbush

TIPRANKS
·
Aug 10

Truist Adjusts Price Target on Protagonist Therapeutics to $170 From $145, Maintains Buy Rating

MT Newswires Live
·
Aug 10

Protagonist Therapeutics, Inc. : JP Morgan Raises Target Price to $149 from $113

THOMSON REUTERS
·
Aug 10

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Protagonist Therapeutics (PTGX) and Zoetis (ZTS)

TIPRANKS
·
Aug 07

Protagonist Therapeutics price target raised to $153 from $151 at Barclays

TIPRANKS
·
Aug 06

Protagonist Therapeutics, Inc. : Leerink Partners Raises Target Price to $150.00 from $110.00

THOMSON REUTERS
·
Aug 06

Protagonist Therapeutics reports Q2 EPS $2.29, consensus $1.93

TIPRANKS
·
Aug 06

Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate

Benzinga Earnings
·
Aug 06